C Ashley Finlen Copeland
Overview
Explore the profile of C Ashley Finlen Copeland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vock D, Durheim M, Tsuang W, Finlen Copeland C, Tsiatis A, Davidian M, et al.
Ann Am Thorac Soc
. 2016 Oct;
14(2):172-181.
PMID: 27779905
Rationale: Lung transplantation is an accepted and increasingly employed treatment for advanced lung diseases, but the anticipated survival benefit of lung transplantation is poorly understood. Objectives: To determine whether and...
2.
DerHovanessian A, Todd J, Zhang A, Li N, Mayalall A, Finlen Copeland C, et al.
Ann Am Thorac Soc
. 2016 May;
13(5):627-35.
PMID: 27144793
Rationale: The clinical course of chronic lung allograft dysfunction (CLAD) is heterogeneous. Forced vital capacity (FVC) loss at onset, which may suggest a restrictive phenotype, was associated with worse survival...
3.
Snyder L, Chan C, Kwon D, Yi J, Martissa J, Finlen Copeland C, et al.
Am J Respir Crit Care Med
. 2015 Sep;
193(1):78-85.
PMID: 26372850
Rationale: Cytomegalovirus (CMV), which is one of the most common infections after lung transplantation, is associated with chronic lung allograft dysfunction and worse post-transplantation survival. Current approaches for at-risk patients...
4.
Todd J, Jain R, Pavlisko E, Finlen Copeland C, Reynolds J, Snyder L, et al.
Am J Respir Crit Care Med
. 2013 Dec;
189(2):159-66.
PMID: 24325429
Rationale: Emerging evidence suggests a restrictive phenotype of chronic lung allograft dysfunction (CLAD) exists; however, the optimal approach to its diagnosis and clinical significance is uncertain. Objectives: To evaluate the...
5.
Vock D, Tsiatis A, Davidian M, Laber E, Tsuang W, Finlen Copeland C, et al.
Biometrics
. 2013 Oct;
69(4):820-9.
PMID: 24128090
Because the number of patients waiting for organ transplants exceeds the number of organs available, a better understanding of how transplantation affects the distribution of residual lifetime is needed to...
6.
Tsuang W, Vock D, Finlen Copeland C, Lederer D, Palmer S
Ann Intern Med
. 2013 May;
158(9):650-7.
PMID: 23648947
Background: Lung transplantation is an effective treatment for patients with advanced lung disease. In the United States, lungs are allocated on the basis of the lung allocation score (LAS), a...
7.
Finlen Copeland C, Vock D, Pieper K, Mark D, Palmer S
Chest
. 2012 Nov;
143(3):744-750.
PMID: 23188377
Background: Quality of life (QOL) is an important but understudied outcome after lung transplantation. Previous cross-sectional, single-center studies suggest improved QOL, but few prior longitudinal multicenter data exist regarding the...
8.
Finlen Copeland C, Davis W, Snyder L, Banks M, Avery R, Davis R, et al.
J Heart Lung Transplant
. 2011 Apr;
30(9):990-6.
PMID: 21489817
Background: The optimal approach to cytomegalovirus (CMV) prevention after lung transplantation is controversial. We recently completed a prospective, randomized, placebo-controlled study of CMV prevention in lung transplantation that demonstrated the...
9.
Finlen Copeland C, Snyder L, Zaas D, Turbyfill W, Davis W, Palmer S
Am J Respir Crit Care Med
. 2010 May;
182(6):784-9.
PMID: 20508211
Rationale: Despite the importance of bronchiolitis obliterans syndrome (BOS) in lung transplantation, little is known regarding the factors that influence survival after the onset of this condition, particularly among bilateral...